Press Releases

Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR) Anticipates submitting an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML) Expects to submit an IND or

Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system provides potentially curative approach to AAT deficiency CAMBRIDGE, Mass. , Dec.

Lead immuno-oncology development candidate NTLA-5001 shows high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemias Proprietary process enhances tumor control in pre clinical models and enables efficient, scalable genome editing

CAMBRIDGE, Mass. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the closing of an underwritten public offering of

CAMBRIDGE, Mass. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the pricing of an underwritten public offering of

CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today that it has commenced an underwritten public

Funding from the Bill and Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients CAMBRIDGE, Mass. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill and Melinda

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression
First-ever in vivo CRISPR treatment delivered intravenously to a patient

On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR) , following regulatory authorization to initiate Phase 1 clinical trial Anticipate s submit ting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001   for the treatment of

CAMBRIDGE, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its third quarter 2020 financial results and operational